DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

Novartis

NYSE: NVS

84.67 0.26 (0.31%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVS $84.67 0.31%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $84.35
Previous Close $84.41
Daily Range $84.13 - $84.89
52-Week Range $67.67 - $85.23
Market Cap $205.4B
P/E Ratio 22.81
Dividend (Yield) $2.72 (2.1%)
Ex-Dividend Date
Dividend Pay Date
02/27/14
04/10/14
Volume 969,607
Average Daily Volume 1,541,388
Current FY EPS $5.24

Sector

Healthcare

Industry

Drugs

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary Rss Feed

ARIAD Pharmaceuticals, Inc. Battling Back

Since returning to market, ARIAD Pharmaceuticals has captured about half of the patients on Iclusig before it went off the market, but it'll have a hard time competing with Novartis' and Bristol-Myers Squibb's leukemia drugs.

Roche Meets Sales Estimates in Q1 - Analyst Blog

Roche Meets Sales Estimates in Q1 - Analyst Blog

Why ThromboGenics (TBGNF) Stock Is Higher Today

Cyclacel Pharmaceuticals, Inc. (CYCCP) Ex-Dividend Date Scheduled for April 15, 2014

Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race

China Biotech In Review: WuXi Receives Award For cGMP Cell-Culture-Based Biologics Production Facili

China Biotech In Review: WuXi Receives Award For cGMP Cell-Culture-Based Biologics Production Facility

Update on BioLineRx's BL-8040 - Analyst Blog

Balanced Risk-Reward for The Cooper Companies - Analyst Blog

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

3 Stocks Pushing The Drugs Industry Downward

Are Tapeworms The Conceptual Key To The Next Multiple Sclerosis Blockbuster?

See More NVS News...

NVS's Top Competitors

NVS $84.67 (0.31%)
Current stock: NVS
JNJ $98.96 (0.21%)
Current stock: JNJ
PFE $30.25 (0.53%)
Current stock: PFE
GSK $52.51 (-0.59%)
Current stock: GSK